Literature DB >> 15971088

[Health economics studies in dermatology].

C Rogalski1, J Simon, U Paasch.   

Abstract

Because of reduced resources for health care, provision of modern effective dermatologic care for patients with German public health insurances has become more and more difficult. This survey is designed to aid in the assessment of published health economic studies as well as encourage participation in health economic evaluations. These studies should analyze and optimize the allocation of the available resources. Four main approaches can be used to calculate the incidental expenses; they differ in their methods of evaluation and assessment of health services. They all offer methods to calculate the anticipated costs and consequences. The methods include cost minimization analysis (CMA), cost effectiveness analysis (CEA), cost utility analysis (CUA) or cost benefit analysis (CBA). Many subgroups also exist. Important criteria for the evaluation of health economic trials and hints for the publication of the results are provided on the basis of the recommendations for health economic evaluations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 15971088     DOI: 10.1007/s00105-005-0982-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  10 in total

Review 1.  Economic analysis in dermatology.

Authors:  Charles N Ellis; Kristin L Reiter; John R C Wheeler; A Mark Fendrick
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

2.  Principles of pharmacoeconomic analysis of drug therapy.

Authors:  D A Freund; R S Dittus
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

3.  Cost effectiveness of community leg ulcer clinics: randomised controlled trial.

Authors:  C J Morrell; S J Walters; S Dixon; K A Collins; L M Brereton; J Peters; C G Brooker
Journal:  BMJ       Date:  1998-05-16

4.  Economic evaluation and health care. What does it mean?

Authors:  R Robinson
Journal:  BMJ       Date:  1993-09-11

5.  Multicentre randomised control trial comparing real time teledermatology with conventional outpatient dermatological care: societal cost-benefit analysis.

Authors:  R Wootton; S E Bloomer; R Corbett; D J Eedy; N Hicks; H E Lotery; C Mathews; J Paisley; K Steele; M A Loane
Journal:  BMJ       Date:  2000-05-06

6.  The cost-effectiveness of isotretinoin in the treatment of acne. Part 3. A cost-minimisation pharmaco-economic model.

Authors:  F Wessels; A N Anderson; K Kropman
Journal:  S Afr Med J       Date:  1999-07

7.  A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma.

Authors:  A Messori; P Becagli; S Trippoli; E Tendi
Journal:  Eur J Cancer       Date:  1997-08       Impact factor: 9.162

Review 8.  The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology.

Authors:  H Williams; K Adetugbo; A L Po; L Naldi; T Diepgen; D Murrell
Journal:  Arch Dermatol       Date:  1998-12

9.  Psoriasis treatment and a day-care centre: clinical aspects and an attempt at a cost-benefit analysis.

Authors:  O Larkö; G Swanbeck
Journal:  Acta Derm Venereol       Date:  1982       Impact factor: 4.437

10.  Quantifying the harmful effect of psoriasis on health-related quality of life.

Authors:  Stefan C Weiss; Alexa B Kimball; David J Liewehr; Andrew Blauvelt; Maria L Turner; Ezekiel J Emanuel
Journal:  J Am Acad Dermatol       Date:  2002-10       Impact factor: 11.527

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.